Introduction {#s1}
============

In the United States, pandemic 2009--2010 influenza A (pH1N1) was first identified in April 2009 [@pone.0060845-Dawood1]. Two waves of infection followed, accounting for an estimated 61 million cases, 274,000 hospitalizations, and 12,470 deaths [@pone.0060845-Centers1], [@pone.0060845-Altmann1]. Compared to seasonal averages, there was an increase in hospitalizations and a decrease in mortality. Children experienced a greater burden of disease and a disproportionately increased burden of mortality [@pone.0060845-Mazick1]--[@pone.0060845-Cox2]. However, the majority of children did not progress to severe disease [@pone.0060845-Riley1]. In contrast, fewer adults were afflicted but proportionally more experienced severe disease [@pone.0060845-LarrauriCamara1]. The clinical characteristics of pH1N1-infected individuals are well described [@pone.0060845-Bautista1]--[@pone.0060845-Li1].

In pediatrics, viral co-infection is frequently encountered but the clinical consequences remain unclear. Co-infection occurs in 25--40% of children with bronchiolitis [@pone.0060845-Miron1]--[@pone.0060845-Richard1]. Viral co-infection also increases the likelihood of requiring pediatric intensive care unit (PICU) level of care [@pone.0060845-ParanhosBaccala1]. These findings may reflect certain combinations of co-infection. For example, infection with respiratory syncytial virus (RSV) and metapneumovirus is associated with a 10-fold greater likelihood of PICU level of care [@pone.0060845-Semple1]. Although some studies revealed similar findings with RSV and rhinovirus co-infection [@pone.0060845-Foulongne1]--[@pone.0060845-Aberle1], others have not confirmed this finding [@pone.0060845-GarciaGarcia1]--[@pone.0060845-Greensill1] or have found less severe disease with viral co-infection [@pone.0060845-Martin1], [@pone.0060845-Canducci1]. In adults the clinical significance of co-infection is poorly understood. It accounts for approximately 5% (range 2%--16%) [@pone.0060845-Drews1]--[@pone.0060845-Nisii1] of adult viral acute respiratory infections, with varying prevalence of specific pairs of viruses [@pone.0060845-Druce1]--[@pone.0060845-Lee1]. Co-infection during the 2009--2010 pH1N1 season varied as well [@pone.0060845-Nisii1], [@pone.0060845-Esper1]. One study found pH1N1 co-infection with rhinovirus correlated with a lower clinical severity, whereas pH1N1 co-infection with other viruses led to greater severity [@pone.0060845-Esper1].

Few studies have examined the clinical characteristics of co-infected patients [@pone.0060845-ParanhosBaccala1], [@pone.0060845-Foulongne1], [@pone.0060845-Nisii1], [@pone.0060845-Franz1]--[@pone.0060845-Yu1] and their outcomes [@pone.0060845-Aberle1], [@pone.0060845-Druce1], [@pone.0060845-Esper1], [@pone.0060845-Randolph1]--[@pone.0060845-Cordero1]. Some have described an association between pH1N1 viral co-infection and poorer outcomes [@pone.0060845-Esper1], [@pone.0060845-Goka1], [@pone.0060845-Kouni1], whereas others have not demonstrated differences in outcomes [@pone.0060845-Randolph1], [@pone.0060845-NavarroMari1], [@pone.0060845-Blyth1]--[@pone.0060845-Camargo1]. Many of these studies are limited by small sample size. Furthermore, direct comparisons are limited by varying age groups and a wide array of acuity that ranges from outpatient to exclusively critical care settings. We previously compared patients with pH1N1to those infected with other respiratory viruses [@pone.0060845-Chan1]. In the present study, we describe the characteristics and outcomes of co-infected patients at our institution at the height of the pH1N1 pandemic.

Materials and Methods {#s2}
=====================

Study Design {#s2a}
------------

A retrospective cohort study was performed of all individuals presenting to our hospital system between October 16, 2009 and December 1, 2009 who were hospitalized and had a positive respiratory viral panel (RVP, Luminex xTAG®; Luminex Corporation, Austin, TX) within 72 hours of hospital admission. Clinical history, laboratory data, medications, radiographic imaging, and hospital course were reviewed as previously described [@pone.0060845-Chan1]. Patients co-infected with two or more viruses, excluded from the initial study, were the focus of this analysis. We hypothesized that infection with certain combinations of respiratory viruses, particularly those with influenza pH1N1, would have worse outcomes than mono-infected patients.

Chart review was done to assess for complications such as treatment for bacterial pneumonia, aspiration pneumonia, metabolic acidosis, acute kidney injury, febrile seizure, chronic obstructive pulmonary disease exacerbation, peritonitis, and hypotension requiring vasopressors. Treatment for bacterial pneumonia was defined as reported in the discharge diagnosis, chart review, or the explicit use of antibiotics for this purpose. Antibiotics empirically started and later discontinued did not fulfill this criterion.

Ethics Statement {#s2b}
----------------

The Rhode Island Hospital institutional review board approved this study. A waiver of informed consent was obtained.

Statistical Analysis {#s2c}
--------------------

Initial analyses examined the frequencies and percentages of categorical variables, and the means and standard deviations of continuous variables. Age was determined to be a significant covariate for many outcome variables of interest, and all subsequent analyses included age as a covariate and only the age-adjusted results are reported. Age as a variable was highly skewed and not normally distributed. Thus, a natural log transformation was used in covariate-adjusted analyses. Several continuous outcome variables (duration of symptoms pre-admission, length of intensive care unit \[ICU\] stay, length of hospital stay, WBC, and percent bands) were also not normally distributed and a natural log transformation was also used to normalize these variables before analysis. Logistic regression, adjusting for age, was used to examine all categorical outcomes, with results reported based on Wald tests with associated odds ratios and their 95% confidence intervals. Analysis of covariance (ANCOVA), adjusting for age, was used to examine all continuous variables. ANCOVA results report the covariate-adjusted F-test p-values and the adjusted outcome means with their standard errors and 95% confidence intervals. All adjusted natural log transformed outcome variables were transformed back into their original metric in tabled values. Analyses were performed using IBM SPSS version 20.

Results {#s3}
=======

A total of 1,192 inpatient RVP samples were performed from October 2009 to December 2009. Six hundred and fifteen were positive for a single respiratory virus, and 52 with two viruses. No samples showed infection with three or more viruses. Review of the 52 co-infected samples revealed two samples where detection of a second virus was initially indeterminate but later finalized as negative, and were therefore reclassified as mono-infection. Additionally, a separate co-infected patient was found to have two specimens. Therefore, 617 (51.8%) inpatients with a single agent identified in their RVP were compared to 49 (4.1%) patients with co-infection (see [Table 1](#pone-0060845-t001){ref-type="table"}).

10.1371/journal.pone.0060845.t001

###### Respiratory viral co-infection (N = 49).

![](pone.0060845.t001){#pone-0060845-t001-1}

  ---------------------------------------- ----
  Influenza A/pH1N1 and Rhinovirus          17
  Adenovirus and Rhinovirus                 10
  RSV-A and Rhinovirus                      5
  Rhinovirus and Parainfluenza IV           4
  Influenza A/pH1N1 and RSV-A               2
  RSV-A and Adenovirus                      2
  Influenza A/pH1N1 and Adenovirus          1
  Influenza A/pH1N1 and Metapneumovirus     1
  Influenza A/pH1N1 and Parainfluenza II    1
  Influenza A/pH1N1 and Parainfluenza IV    1
  Influenza A/pH1N1 and RSV-B               1
  Rhinovirus and Parainfluenza I            1
  RSV-A and Coronavirus (HKUI)              1
  RSV-A and Parainfluenza IV                1
  RSV-B and Rhinovirus                      1
  ---------------------------------------- ----

By uncorrected chi-square analysis, pH1N1 was identified in 49% (24/49) of the co-infected group and 47% (290/617) of the mono-infected control group (p = 0.8). No seasonal influenza A H3 or influenza B was encountered in either group. In co-infected patients, rhinovirus was observed most frequently \[78% (38/49) of co-infected and 34% (208/617) of mono-infected patients, respectively (OR 6.8, 95% CI 3.4--13.6, p\<0.001)\]. RSV A affected 22% (11/49) of the co-infected and 5.8% (36/617) of mono-infected patients, respectively (OR 4.7, 95% CI 2.2--10.0, p\<0.001). Adenovirus was present in 27% (13/49) of the co-infected and 4.4% (27/617) of mono-infected patients, respectively (OR 7.9, 95% CI 3.8--16.6, p\<0.001). Parainfluenza 4 was present in 12% (6/49) and 2.3% (14/617) of the co-infected and mono-infected patients, respectively, (OR 6.0, 95% CI 2.2--16.4, p\<0.001).

Co-infection with any combination of respiratory viruses compared to mono-infection with any single virus was associated with younger age (mean 8.8 years of age compared to 21 years of age, respectively, p\<0.001; [Figure 1](#pone-0060845-g001){ref-type="fig"}). To adjust for these differences, all subsequent analyses were performed with age as a covariate.

![Distribution of respiratory virus co-infection versus mono-infection relative to age group.](pone.0060845.g001){#pone-0060845-g001}

Co-infection with any combination of respiratory viruses compared to mono-infection with any single virus was associated with age less than five years (OR 3.2, 95% CI 1.5--6.8, p = 0.003; [Table 1](#pone-0060845-t001){ref-type="table"}). All co-infected patients were under 60 years of age ([Figure 1](#pone-0060845-g001){ref-type="fig"}). Co-infected patients more frequently reported sick contacts (OR 2.0, 95% CI 1.1--3.6, p = 0.02). Co-infected patients were more frequently HIV seropositive (OR 5.5, 95% CI 1.1--27.7, p = 0.04; [Table 2](#pone-0060845-t002){ref-type="table"}). Co-infected patients were more likely to present with complaints of fever/chills, and were more frequently tachypneic at presentation (36.4±1.7 breaths per minute in co-infected patients compared to 32.5±0.5 breaths per minute in mono-infected patients, p = 0.03). Both groups had similar numbers of chest radiographs (84% and 86% of co-infected and mono-infected patients, respectively). Co-infection was more often associated with interstitial opacities (OR 7.5, 95% CI 3.4--16.5, p\<0.001).

10.1371/journal.pone.0060845.t002

###### Age-adjusted characteristics in patients with respiratory viral co-infection compared to mono-infection.

![](pone.0060845.t002){#pone-0060845-t002-2}

                                                                                   Co-infected (n = 49)       Mono-infected (n = 617)       Odds Ratio \[95% CI\]       p-value
  ----------------------------------------------------------------------------- -------------------------- ----------------------------- --------------------------- -------------
  **Age (years)**                                                                                                                                                    
  \<5                                                                                    57% (28)                    38% (237)                3.2 \[1.5--6.8\]           .003
  5 to 18                                                                                25% (12)                    23% (139)                2.3 \[0.95--5.6\]           .07
  \>18[a](#nt101){ref-type="table-fn"}                                                   18% (9)                     39% (241)                                       
  Sex (male)                                                                             67% (33)                    53% (329)                1.6 \[0.9--3.1\]            .12
  **Past Medical History**                                                                                                                                           
  Sick contacts                                                                          53% (26)                    34% (210)                2.0 \[1.1--3.6\]            .02
  Visited emergency department or clinic pre-admission                                   57% (28)                    49% (300)                1.3 \[0.7--2.4\]            .4
  Antimicrobial agents pre-admission                                                     18% (9)                     24% (147)                0.8 \[0.4--1.6\]            .5
  Duration of symptoms pre-admission[b](#nt102){ref-type="table-fn"}                 3.0 \[2.4--3.8\]            2.5 \[2.3--2.7\]                                         .1
  Respiratory disease                                                                    47% (23)                    45% (275)                1.4 \[0.7--2.5\]            .3
  Asthma                                                                                 27% (13)                    37% (230)                0.8 \[0.4--1.7\]            .6
  Hepatic disease[c](#nt103){ref-type="table-fn"}                                        0.0% (0)                    2.9% (18)                                            .6
  Renal disease[c](#nt103){ref-type="table-fn"}                                          0.0% (0)                    2.4% (15)                                            .2
  Cancer                                                                                 4.1% (2)                    6.0% (37)                1.3 \[0.3--5.8\]            .8
  Neurologic disease                                                                     8.2% (4)                    11% (69)                 0.8 \[0.3--2.4\]            .7
  Cardiac disease                                                                        6.1% (3)                   12.5% (77)                0.7 \[0.2--2.2\]            .5
  Immunocompromised                                                                      8.2% (4)                    6.2% (38)                2.2 \[0.7--6.8\]            .2
  HIV                                                                                    4.1% (2)                    1.8% (11)                5.5 \[1.1--27.7\]           .04
  Admission from a skilled nursing facility[c](#nt103){ref-type="table-fn"}              0.0% (0)                    2.1% (13)                                            .7
  Tobacco use (current or exposed)                                                       8.2% (4)                    16% (96)                 0.7 \[0.2--2.1\]            .5
  Pregnant[c](#nt103){ref-type="table-fn"}                                               0.0% (0)                    1.3% (8)                                             .6
  Patient receiving aspirin[c](#nt103){ref-type="table-fn"}                              0.0% (0)                    9.6% (59)                                            .3
  **Clinical Symptoms**                                                                                                                                              
  Fever/chills                                                                           92% (45)                    80% (495)                3.1 \[1.1--8.8\]            .04
  Mental status, lethargy, irritability, seizure, other neurologic disease               41% (20)                    31% (189)                1.0 \[0.5--1.9\]            .9
  Weakness                                                                               10% (5)                     17% (106)                0.9 \[0.3--2.6\]            .9
  Fatigue                                                                                8.2% (4)                    15% (92)                  0.6 \[.2--1.7\]            .3
  Conjunctivitis                                                                         6.1% (3)                    2.1% (13)                2.3 \[0.6--8.5\]            .2
  Rash[c](#nt103){ref-type="table-fn"}                                                   0.0% (0)                    4.5% (28)                                            .02
  Cough                                                                                  94% (46)                    88% (545)                2.4 \[0.7--8.1\]            .2
  Productive                                                                             10% (5)                     18% (113)                0.9 \[0.3--2.4\]            .8
  Nasal symptoms                                                                         74% (36)                    57% (349)                1.6 \[0.8--3.2\]            .2
  Sore throat                                                                            8.2% (4)                    24% (145)                 0.4 \[.1--1.2\]            .1
  Headache                                                                               12% (6)                     20% (121)                0.9 \[0.4--2.4\]            .9
  Myalgia                                                                                12% (6)                     21% (127)                1.1 \[0.4--3.0\]            .9
  Arthralgia                                                                             2.0% (1)                    1.9% (12)                2.1 \[0.3--17.3\]           .5
  Chest pain                                                                             12% (6)                     16% (101)                1.4 \[0.5--3.8\]            .5
  Dyspnea                                                                                74% (36)                    59% (362)                1.9 \[0.99--3.7\]           .05
  Wheezing                                                                               43% (21)                    28% (173)                1.8 \[0.98--3.2\]           .06
  Nausea                                                                                 12% (6)                     19% (117)                1.0 \[0.4--2.6\]            1.0
  Vomiting                                                                               37% (18)                    34% (211)                1.0 \[0.5--1.8\]            1.0
  Abdominal pain                                                                         12% (6)                     11% (66)                 1.5 \[0.6--3.7\]            .4
  Diarrhea                                                                               8.2% (4)                    13% (80)                  0.7 \[.2--1.9\]            .5
  Anorexia                                                                               57% (28)                    38% (232)                1.6 \[0.9--3.0\]            .1
  **Presenting Vital Signs** [d](#nt104){ref-type="table-fn"}                                                                                                        
  Initial temperature (°F)                                                               99.9±0.3                    99.7±0.1                                             .6
  Maximum temperature (°F)                                                              100.9±0.3                    100.5±0.1                                            .2
  Initial heart rate (/min)                                                               131±3                        130±1                                              .9
  Maximum heart rate (/min)                                                               136±3                        136±1                                              1.0
  Initial respiratory rate (/min)                                                          36±2                        33±1                                               .03
  Maximum respiratory rate (/min)                                                          39±2                        36±1                                               .08
  Admission chest X-ray Performed                                                        84% (41)                    86% (531)                1.1 \[0.5--2.5\]            .8
  **Comparison of Chest Radiograph Results** [e](#nt105){ref-type="table-fn"}    **Co-infected (n = 41)**   **Mono-infected (n = 531)**   **Odds Ratio \[95% CI\]**   **p-value**
  NAD                                                                                    22% (9)                     51% (273)                0.3 \[0.1--0.7\]           .003
  IO                                                                                     61% (25)                    16% (86)                 7.5 \[3.4--16.5\]         \<.001
  FASD                                                                                   29% (12)                    20% (105)                1.7 \[0.8--3.4\]            .1
  MFASD[c](#nt103){ref-type="table-fn"}                                                   0% (0)                     9.6% (51)                                            .05
  Edema[c](#nt103){ref-type="table-fn"}                                                   0% (0)                     3.0% (16)                                            .6
  Effusion[c](#nt103){ref-type="table-fn"}                                                0% (0)                     1.9% (10)                                            .5
  Pneumomediastinum[c](#nt103){ref-type="table-fn"}                                       0% (0)                     0.6% (3)                                             .6
  Collapse[c](#nt103){ref-type="table-fn"}                                                0% (0)                     0.2% (1)                                             .8
  **Lab Results**                                                                **Co-infected (n = 38)**   **Mono-infected (n = 435)**                              
  WBC[b](#nt102){ref-type="table-fn"}                                               9.4 \[7.9--11.2\]            9.2 \[8.8--9.7\]                                         .9
                                                                                 **Co-infected (n = 38)**   **Mono-infected (n = 424)**                              
  Percent bands[b](#nt102){ref-type="table-fn"}                                      0.9 \[0.4--1.6\]            1.0 \[0.8--1.2\]                                         .7

Reference category.

Back transformation of the mean age-adjusted natural log values analyzed, along with back transformed 95% confidence intervals.

Odds ratios not computed on variables with zero occurrences in a cell category.

Adjusted means and standard errors are presented.

NAD: No acute disease; IO: interstitial opacities; FASD: focal airspace disease; MFASD: multifocal airspace disease.

Once hospitalized, oseltamivir was used more often in co-infected than mono-infected patients \[80% (39/49) and 62% (385/617), respectively, OR 3.3, 95% CI 1.6--7.0, p = 0.001\]. More co-infected patients received antibacterial agents compared to mono-infected patients \[76% (37/49) and 55% (337/617), respectively, OR 3.1, 95% CI 1.6--6.2, p = 0.001, [Table 3](#pone-0060845-t003){ref-type="table"}\].

10.1371/journal.pone.0060845.t003

###### Age-adjusted treatments and outcomes in patients with respiratory viral co-infection compared to mono-infection.

![](pone.0060845.t003){#pone-0060845-t003-3}

                                                             Co-infected (n = 49)   Mono-infected (n = 617)   Odds Ratio \[95% CI\]   p-value
  --------------------------------------------------------- ---------------------- ------------------------- ----------------------- ---------
  **Treatment**                                                                                                                      
  Oseltamivir                                                      80% (39)                62% (385)            3.3 \[1.6--7.0\]       .001
  Zanamivir (inhaled)                                              2.0% (1)                0.2% (1)             24 \[1.4--400.5\]       .03
  Peramivir[a](#nt106){ref-type="table-fn"}                         0% (0)                 0.5% (3)                                     .7
  Ribavirin[a](#nt106){ref-type="table-fn"}                         0% (0)                 0.2% (1)                                     .9
  Antibiotics                                                      76% (37)                55% (337)            3.1 \[1.6--6.2\]       .001
  Steroids                                                         53% (26)                41% (252)            1.9 \[1.03--3.4\]       .04
  Admissions to any ICU                                            25% (12)                17% (104)            1.6 \[0.8--3.2\]        .2
  ICU length of stay[b](#nt107){ref-type="table-fn"}           3.5 \[2.1--5.7\]        2.9 \[2.5--3.4\]                                 .5
  Intubation                                                       8.2% (4)                3.7% (23)            2.8 \[0.9--8.8\]        .07
  Positive airway pressure                                         2.0% (1)                3.6% (22)            1.0 \[0.1--7.9\]        1.0
  Hi-flow nasal cannula                                            16% (8)                 9.1% (56)            1.4 \[0.6--3.3\]        .4
  Vasopressor use                                                  4.1% (2)                1.8% (11)            3.2 \[0.7--15.5\]       .2
  Nebulizers or inhalers                                           63% (31)                53% (324)            1.6 \[0.9--2.9\]        .1
  **Outcome**                                                                                                                        
  Hospital length of stay[b](#nt107){ref-type="table-fn"}      3.3 \[2.7--4.0\]        2.8 \[2.6--2.9\]                                 .1
  Complications                                                    37% (18)                23% (142)            3.5 \[1.8--7.0\]      \<.001
  Treatment for bacterial pneumonia alone                          31% (15)                9.2% (57)            6.8 \[3.3--14.2\]     \<.001
  Death                                                            2.0% (1)                1.1% (7)             4.0 \[0.4--35.2\]       .2

Odds Ratios not computed on variables with zero occurrences in a cell category.

Back transformation into days, of the mean age-adjusted natural log values analyzed, along with the back transformed 95% confidence intervals. Analysis conducted on data available on 114 of 116 admitted to ICU.

Among co-infected patients, 15 (31%) were treated for a potential bacterial pneumonia, 4 (8.2%) had respiratory isolates sent for analysis, with confirmation of a bacterial pneumonia in one patient (2.0%). In contrast, 57 (9.2%) mono-infected patients were treated for a potential bacterial pneumonia. Respiratory isolates were obtained in 60 patients (9.7%), with identification of a causative pathogen in 17 (2.8%). An additional three patients had *Streptococcus pneumoniae* bacteremia. Co-infected patients were more likely to experience complications (OR 3.5, 95% CI 1.8--7.0, p\<0.001), particularly treatment for a secondary bacterial pneumonia (OR 6.8, 95% CI 3.3--14.2, p\<0.001). Most (72%) patients treated for a secondary bacteria pneumonia were infected with pH1N1.

Further analysis was performed of patients co-infected with pH1N1 and another respiratory virus (n = 24) compared with pH1N1 mono-infection (n = 290). Of patients co-infected with pH1N1, 71% had rhinovirus, 8.3% RSV A, 4.2% RSV B, 4.2% adenovirus, 4.2% metapneumovirus, 4.2% parainfluenza II, and 4.2% with parainfluenza IV. Co-infected pH1N1 patients, when compared to mono-infected pH1N1 patients were younger (mean age of 14 years and 23 years, respectively, p = 0.04; [Figure 2](#pone-0060845-g002){ref-type="fig"}). Because of the unequal distribution of age, we performed all subsequent analyses with age as a covariate. Once performed, pH1N1 co-infection, as compared to pH1N1 mono-infection, was not significantly associated with any age category.

![Distribution of pH1N1 co-infection versus pH1N1 mono-infection relative to age group.](pone.0060845.g002){#pone-0060845-g002}

PH1N1 co-infected patients were more likely to be immunocompromised, particularly with HIV infection. Co-infected pH1N1 patients more often complained of dyspnea and symptoms consistent with conjunctivitis. Co-infected pH1N1 patients were more likely to have interstitial opacities on their admission chest radiograph ([Table 4](#pone-0060845-t004){ref-type="table"}).

10.1371/journal.pone.0060845.t004

###### Age-adjusted characteristics in patients with pH1N1 influenza viral co-infection compared to pH1N1 mono-infection.

![](pone.0060845.t004){#pone-0060845-t004-4}

                                                                                   Co-infected (n = 24)       Mono-infected (n = 290)       Odds Ratio \[95% CI\]       p-value
  ----------------------------------------------------------------------------- -------------------------- ----------------------------- --------------------------- -------------
  **Age (years)**                                                                                                                                                    
  \<5                                                                                    29% (7)                     21% (62)                 2.2 \[0.8--6.7\]            .1
  5 to 18                                                                                42% (10)                    31% (89)                 2.2 \[0.8--6.1\]            .1
  \>18[a](#nt108){ref-type="table-fn"}                                                   29% (7)                     48% (139)                                       
  Sex (male)                                                                             63% (15)                    53% (153)                1.4 \[0.6--3.3\]            .5
  **Past Medical History**                                                                                                                                           
  Sick contacts                                                                          54% (13)                    43% (124)                1.4 \[0.6--3.2\]            .5
  Visited an emergency department or clinic pre-admission                                54% (13)                    49% (143)                1.1 \[0.5--2.6\]            .8
  Antimicrobial agents pre-admission                                                     17% (4)                     24% (69)                 0.6 \[0.2--1.8\]            .4
  Duration of symptoms pre-admission[b](#nt109){ref-type="table-fn"}                 3.2 \[2.4--4.4\]            2.4 \[2.2--2.6\]                                         .06
  Respiratory disease                                                                    54% (13)                    47% (135)                1.5 \[0.6--3.5\]            .4
  Asthma                                                                                 33% (8)                     40% (115)                1.0 \[0.4--2.4\]            .9
  Hepatic disease[c](#nt110){ref-type="table-fn"}                                         0% (0)                     4.1% (12)                                            .5
  Renal disease[c](#nt110){ref-type="table-fn"}                                           0% (0)                     2.4% (7)                                             .4
  Cancer                                                                                 8.3% (2)                    2.8% (8)                 3.7 \[0.7--19.3\]           .1
  Neurologic disease                                                                     4.2% (1)                    13% (37)                 0.3 \[0.04--2.2\]           .2
  Cardiac disease                                                                        8.3% (2)                    9.7% (28)                1.1 \[0.2--5.0\]            .9
  Immunocompromised                                                                      17% (4)                     4.8% (14)                5.5 \[1.6--19.6\]          .008
  HIV                                                                                    8.3% (2)                    1.4% (4)                11.2 \[1.8--70.8\]          .010
  Admitted from skilled nursing facility[c](#nt110){ref-type="table-fn"}                  0% (0)                     0.7% (2)                                             .8
  Tobacco use                                                                            13% (3)                     21% (61)                 0.6 \[0.2--2.2\]            .5
  Pregnant[c](#nt110){ref-type="table-fn"}                                                0% (0)                     1.4% (4)                                             .6
  Patient on aspirin[c](#nt110){ref-type="table-fn"}                                      0% (0)                     7.6% (22)                                            .4
  **Clinical Symptoms**                                                                                                                                              
  Fever/chills[c](#nt110){ref-type="table-fn"}                                          100% (24)                    92% (266)                                            .2
  Mental status, lethargy, irritability, seizure, other neurologic disease               17% (4)                     25% (72)                 0.3 \[0.1--1.03\]           .06
  Weakness                                                                               17% (4)                     27% (78)                 0.8 \[0.2--2.5\]            .7
  Fatigue                                                                                4.2% (1)                    20% (57)                 0.2 \[.02--1.4\]            .1
  Conjunctivitis                                                                         8.3% (2)                    1.0% (3)                 7.3 \[1.1--47.2\]           .04
  Rash[c](#nt110){ref-type="table-fn"}                                                   0.0% (0)                    4.5% (13)                                            .1
  Cough                                                                                  96% (23)                    91% (264)                2.5 \[0.3--19.7\]           .4
  Productive                                                                             17% (4)                     23% (66)                 1.1 \[0.3--3.6\]            .9
  Nasal symptoms                                                                         58% (14)                    57% (164)                0.9 \[0.4--2.1\]            .8
  Sore throat                                                                            8.3% (2)                    32% (92)                 0.2 \[.1--1.02\]            .05
  Headache                                                                               21% (5)                     30% (86)                 0.8 \[0.3--2.3\]            .7
  Myalgia                                                                                21% (5)                     32% (92)                 0.8 \[0.3--2.5\]            .7
  Arthralgia[c](#nt110){ref-type="table-fn"}                                              0% (0)                     3.1% (9)                                             .6
  Chest Pain                                                                             25% (6)                     23% (68)                 1.6 \[0.6--4.5\]            .4
  Dyspnea                                                                                75% (18)                    53% (153)                3.0 \[1.1--7.8\]            .03
  Wheezing                                                                               38% (9)                     26% (74)                 1.7 \[0.7--4.0\]            .2
  Nausea                                                                                 25% (6)                     31% (91)                 1.0 \[0.4--2.9\]            1.0
  Vomiting                                                                               54% (13)                    39% (113)                1.7 \[0.7--3.9\]            .2
  Abdominal pain                                                                         17% (4)                     15% (42)                 1.2 \[0.4--3.8\]            .7
  Diarrhea                                                                               13% (3)                     16% (46)                  0.8 \[.2--2.8\]            .7
  Anorexia                                                                               50% (12)                    38% (111)                1.2 \[0.5--3.0\]            .7
  **Presenting Vital Signs** [d](#nt111){ref-type="table-fn"}                                                                                                        
  Initial temperature (°F)                                                               99.7±0.4                    99.9±0.1                                             .6
  Maximum temperature (°F)                                                              101.0±0.4                    100.9±0.1                                            .9
  Initial heart rate (/min)                                                               124±5                        123±1                                              .9
  Maximum heart rate (/min)                                                               136±4                        129±1                                              .2
  Initial respiratory rate (/min)                                                          31±2                        28±1                                               .1
  Maximum respiratory rate (/min)                                                          34±2                        32±1                                               .3
  Admission chest plain film performed                                                   83% (20)                    88% (256)                0.8 \[0.3--2.6\]            .7
  **Comparison of Chest Radiograph Results** [e](#nt112){ref-type="table-fn"}    **Co-infected (n = 20)**   **Mono-infected (n = 256)**   **Odds Ratio \[95% CI\]**   **p-value**
  NAD                                                                                    25% (5)                     59% (152)                0.3 \[0.1--0.7\]            .01
  IO                                                                                     55% (11)                    11% (27)                16.9 \[4.5--62.7\]         \<.001
  FASD                                                                                   30% (6)                     20% (51)                 1.6 \[0.6--4.5\]           .340
  MFASD[c](#nt110){ref-type="table-fn"}                                                   0% (0)                     7.4% (19)                                            .2
  Edema[c](#nt110){ref-type="table-fn"}                                                   0% (0)                     2.3% (6)                                             .7
  Effusion[c](#nt110){ref-type="table-fn"}                                                0% (0)                     1.6% (4)                                             .6
  Pneumomediastinum[c](#nt110){ref-type="table-fn"}                                       0% (0)                     0.8% (2)                                             .6
  Collapse[c](#nt110){ref-type="table-fn"}                                                0% (0)                     0.4% (1)                                             .7
  **Lab Results**                                                                **Co-infected (n = 20)**   **Mono-infected (n = 245)**                              
  WBC[b](#nt109){ref-type="table-fn"}                                                7.6 \[6.2--9.3\]            7.7 \[7.3--8.2\]                                         .9
                                                                                 **Co-infected (n = 20)**   **Mono-infected (n = 240)**                              
  Percent bands[b](#nt109){ref-type="table-fn"}                                      1.0 \[0.3--2.1\]            1.0 \[0.7--1.2\]                                         1.0

Reference category.

Back transformation of the mean age-adjusted natural log values analyzed, along with back transformed 95% confidence intervals.

Odds ratios not computed on variables with zero occurrences in a cell category.

Adjusted means and standard errors are presented.

NAD: No acute disease; IO: interstitial opacities; FASD: focal airspace disease; MFASD: multifocal airspace disease.

Patients co-infected with pH1N1 were more likely to experience complications and to receive treatment for a secondary bacterial pneumonia (OR 6.3, 95% CI 2.5--15.8, p\<0.001; [Table 5](#pone-0060845-t005){ref-type="table"}).

10.1371/journal.pone.0060845.t005

###### Age-adjusted treatments and outcomes in patients with pH1N1 influenza viral co-infection compared to pH1N1 mono-infection.

![](pone.0060845.t005){#pone-0060845-t005-5}

                                                             Co-infected (n = 24)   Mono-infected (n = 290)   Odds Ratio \[95% CI\]   p-value
  --------------------------------------------------------- ---------------------- ------------------------- ----------------------- ---------
  **Treatment**                                                                                                                      
  Oseltamivir                                                      92% (22)                79% (229)            3.7 \[0.8--16.5\]       .09
  Zanamivir (inhaled)                                              4.2% (1)                0.3% (1)            18.2 \[1.1--310.3\]      .05
  Peramivir[a](#nt113){ref-type="table-fn"}                         0% (0)                 1.0% (3)                                     .7
  Ribavirin[a](#nt113){ref-type="table-fn"}                         0% (0)                  0% (0)                                      --
  Antibiotics                                                      79% (19)                55% (160)            3.2 \[1.2--8.9\]        .03
  Steroids                                                         63% (15)                34% (99)             4.1 \[1.7--10.2\]      .002
  Admissions to any ICU                                            25% (6)                 16% (47)             1.9 \[0.7--5.0\]        .2
  ICU length of stay[b](#nt114){ref-type="table-fn"}           3.0 \[1.6--5.8\]        3.4 \[2.7--4.3\]                                 .7
  Intubation                                                       8.3% (2)                3.4% (10)            3.3 \[0.7--16.9\]       .1
  Positive airway pressure                                         4.2% (1)                5.2% (15)            1.0 \[0.1--8.4\]        1.0
  Hi-flow nasal cannula                                            13% (3)                 6.9% (20)            1.7 \[0.5--6.3\]        .4
  Vasopressor use                                                  8.3% (2)                2.8% (8)             4.4 \[0.8--23.0\]       .08
  Nebulizer or inhaler use                                         63% (15)                47% (135)            2.2 \[0.9--5.2\]        .09
  **Outcome**                                                                                                                        
  Hospital length of stay[b](#nt114){ref-type="table-fn"}      3.0 \[2.2--4.0\]        2.6 \[2.4--2.8\]                                 .4
  Complications                                                    54% (13)                38% (110)            2.7 \[1.1--6.7\]        .03
  Treatment for bacterial pneumonia alone                          46% (11)                14% (41)             6.3 \[2.5--15.8\]     \<.001
  Death                                                            4.2% (1)                2.1% (6)             3.3 \[0.4--30.7\]       .3

Odds Ratios not computed on variables with zero occurrences in a cell category.

Back transformation into days, of the mean age-adjusted natural log values analyzed, along with the back transformed 95% confidence intervals. Analysis conducted on data available on 114 of 116 admitted to ICU.

Using logistic regression with the reference group composed of mono-infected patients other than pH1N1, all co-infected groups had an increased likelihood of treatment for a secondary bacterial pneumonia, particularly co-infection with pH1N1 (OR 17.8, 95% CI 6.7--47.1). Increasing age was also associated with such treatment (OR 1.5, 95% CI 1.2--1.88, p\<0.001; [Table 6](#pone-0060845-t006){ref-type="table"}).

10.1371/journal.pone.0060845.t006

###### Independent predictors of treatment for a secondary bacterial pneumonia comparing patients with non-pH1N1 mono-infection to other patient groups.
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  Group                                  Odds Ratio \[95% CI\]   p-value
  ------------------------------------- ----------------------- ---------
  pH1N1 alone                              2.7 \[1.5--4.9\]       0.002
  Co-infected, not pH1N1                   6.0 \[1.7--20.9\]      0.005
  Co-infected, pH1N1                      17.8 \[6.7--47.1\]     \<0.001
  Gender                                   1.1 \[0.7--1.9\]        0.7
  Age[a](#nt115){ref-type="table-fn"}      1.5 \[1.2--1.9\]      \<0.001

Age as Nat log (age +1) to adjust for significant variance at the group level and between groups.

Discussion {#s4}
==========

We found 7.4% of hospitalized patients with a positive respiratory viral panel had co-infection, similar to other studies [@pone.0060845-Yang1], [@pone.0060845-Nisii1], [@pone.0060845-Esper1], [@pone.0060845-Randolph1], [@pone.0060845-Pretorius1]. While there were distinct differences in presentation, we did not find a specific prodrome to distinguish respiratory virus co-infection from mono-infection. PH1N1 co-infected patients were more likely to present with interstitial opacities consistent with a viral pneumonia and they were more likely to received treatment for a presumed secondary bacterial pneumonia. However, there were no differences in admission to any ICU, ICU length of stay, or duration of hospitalization. These findings appear incongruent, as other authors have described an association between pH1N1 mono-infection and secondary bacterial pneumonia, which in turn is associated with increased morbidity and mortality [@pone.0060845-Belongia1], [@pone.0060845-Jain1], [@pone.0060845-Nisii1], [@pone.0060845-Lee1], [@pone.0060845-Franz1], [@pone.0060845-Louie1]--[@pone.0060845-Colamussi1]. We used the treatment for a bacterial pneumonia as a surrogate marker for this complication. Only a third of patients treated for a bacterial pneumonia had respiratory specimens submitted. Thus, our ability to microbiologically confirm this diagnosis was limited. Additionally, the misinterpretation of interstitial opacities on admission chest radiographs as representative of bacterial rather than viral pneumonia likely contributed to provider overtreatment.

Overall, we observed a higher frequency of interstitial opacities consistent with viral pneumonia in both co-infection in general, but also with pH1N1 co-infection specifically. There is increasing recognition of the various forms of viral pneumonia associated with pH1N1 [@pone.0060845-BusiRizzi1]--[@pone.0060845-Cunha1] To our knowledge, only one other study has described the association between respiratory virus co-infection and an increased likelihood of a viral pneumonia [@pone.0060845-Esposito1]. The dearth of deep respiratory specimens limits the interpretation of our findings, but the radiographic and clinical characteristics of our patients support the association between respiratory virus co-infection and viral pneumonia.

Co-infection occurred more frequently in younger patients and the likelihood of receiving treatment for a secondary bacterial pneumonia increased with increasing age. Of note, we did not identify any patients with respiratory viral co-infection greater than sixty years of age. This may be secondary to the younger age distribution of our cohort or may be due to other immunologic or host parameters in the aging population in general or particular to pH1N1 [@pone.0060845-Jhung1], [@pone.0060845-Hancock1]. Younger patients may have an absence of protective antibodies or other forms of immunity from limited past exposure to viral pathogens, making co-infection potentially more likely.

While studies during previous seasons have reported a similar likelihood of co-infection as we observed, many studies were limited to the critical care or outpatient setting which may introduce selection bias by virtue of patient acuity [@pone.0060845-Li1], [@pone.0060845-Richard1], [@pone.0060845-Wilkesmann1]--[@pone.0060845-Greensill1], [@pone.0060845-Drews1], [@pone.0060845-Druce1], [@pone.0060845-Kaye1]. While hospitalized patients with respiratory virus co-infection did not experience poorer outcomes in our study, our findings do not address whether it was a risk factor for hospitalization itself. To this end, a large multi-center study across various levels of care is necessary.

In influenza mono-infection, the host response is simultaneously pro- and anti-inflammatory [@pone.0060845-Hall1]. Exceeding these bounds, pH1N1, as compared to seasonal influenza, demonstrates an accentuated pro-inflammatory response, but also a suppressed adaptive immune cytokine response [@pone.0060845-Lee3]--[@pone.0060845-To1]. The pathogenesis of dual respiratory viral infections is unclear. Esper et al found co-infection with pH1N1 and rhinovirus correlated with lower clinical severity, whereas other pH1N1 virus pairs had greater severity, independent of pH1N1 titers [@pone.0060845-Esper1]. Elsewhere, co-infection with RSV and another virus was associated with a decreased IFN-gamma response and ultimately increased severity [@pone.0060845-Aberle1]. Further research into the host cytokine and cellular responses of co-infected patients are needed, as are studies with a more robust microbiologic assessment to distinguish viral from bacterial pneumonia.

Conclusion {#s5}
==========

Respiratory virus co-infection may be associated with differences in disease manifestation and complications, particularly chest radiographic changes suggestive of viral pneumonia and treatment for a presumed secondary bacterial pneumonia. Even when adjusted for pH1N1, which has a known association with bacterial pneumonia, co-infection in all forms was associated with treatment for a bacterial pneumonia. Co-infection with pH1N1 in particular carries the greatest risk for this complication. However, our findings suggest that respiratory virus co-infection is not associated with worse outcomes despite these complications.
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